Clinical reference Biomarker Directory
Back to directory

Mismatch Repair Deficiency / Microsatellite Instability

Established

dMMR/MSI-H is a tissue-agnostic predictive biomarker for checkpoint inhibitor response and the molecular signature of Lynch syndrome.

Also known as MMR MSI-H dMMR MLH1 MSH2 MSH6 PMS2
In plain language

These proteins normally fix DNA copying mistakes. When they stop working, tumors build up so many mutations that the immune system can often recognize and attack them — which is exactly why a specific immunotherapy drug was approved for any cancer type with this feature, a first in oncology. Finding this in a colon or uterine cancer should also prompt genetic testing for an inherited cancer syndrome that runs in families.

Biomarker & context

Mismatch repair (MMR) proteins (MLH1, MSH2, MSH6, PMS2) correct DNA replication errors; loss of function causes microsatellite instability (MSI-H), one of three FDA-approved predictive biomarkers for immune checkpoint inhibitor response and the molecular basis of Lynch syndrome.

What it indicates

dMMR/MSI-H tumors accumulate large numbers of mutations, making them highly responsive to checkpoint inhibitors; pembrolizumab holds a tissue-agnostic FDA approval for any dMMR/MSI-H solid tumor regardless of cancer type, one of the first approvals based purely on a biomarker rather than tumor site of origin.

Diagnosis & clinical testing

MMR protein loss is screened via immunohistochemistry (loss of nuclear staining for one or more of the four proteins); microsatellite instability itself is assessed via PCR-based fragment analysis or NGS comparing microsatellite repeat lengths in tumor versus normal tissue. The two methods are complementary and occasionally discordant, so professional guidelines generally recommend using both when feasible.

Guiding treatment

A dMMR/MSI-H result in colorectal or endometrial cancer should prompt germline genetic testing for Lynch syndrome, since this can be the first clue to a hereditary cancer predisposition affecting the whole family, not just a treatment-selection marker for the individual patient.

Clinical significance

One of the first FDA drug approvals based purely on a biomarker rather than the cancer's site of origin.

References
  1. PMC. (2023). Predictive biomarkers of response to immune checkpoint inhibitors in immuno-oncology.
  2. FDA. Pembrolizumab tissue-agnostic approval for dMMR/MSI-H solid tumors.